Coherus Oncology Reports Encouraging Interim Clinical Data for Tagmokitug in Esophageal Cancer

Coherus Oncology has announced compelling interim clinical data from its Phase 1b/2a trials for tagmokitug, an investigational cytolytic CCR8 antibody, in combination with toripalimab and chemotherapy for patients with esophageal cancer. The data, as of October 14, 2026, showed a confirmed overall response rate of 75% in evaluable front-line esophageal squamous cell carcinoma (ESCC) patients, irrespective of PD-L1 status, and 100% in PD-L1 positive patients. The treatment demonstrated a manageable safety profile with no new safety signals.